Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast for COVID-19 Symptoms
NCT04389411Phase 3Unknown
- Sponsor
- McGill University
- Start
- Nov 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Montelukast with Placebo (2 arms). Primary endpoints: Symptom severity as measured by FluPro PLUS scores and SpO2 levels at 14 days and C-Reactive Protein at 14 days. Status: unknown.
02
Drugs
montelukast
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04389411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04389411.